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Abstract
Background: The number of predictive biomarkers that will be necessary to assess in clinical practice will increase
with the availability of drugs that target specific molecular alterations. Therefore, diagnostic laboratories are confronted
with new challenges: costs, turn-around-time and the amount of material required for testing will increase with the
number of tests performed on a sample. Our consortium of European clinical research laboratories set out to test if
semi-conductor sequencing provides a solution for these challenges.
Methods: We designed a multiplex PCR targeting 87 hotspot regions in 22 genes that are of clinical interest for lung and/
or colorectal cancer. The gene-panel was tested by 7 different labs in their own clinical setting using ion-semiconductor
sequencing.
Results: We analyzed 155 samples containing 112 previously identified mutations in the KRAS, EGFR en BRAF genes.
Only 1 sample failed analysis due to poor quality of the DNA. All other samples were correctly genotyped for the
known mutations, even as low as 2%, but also revealed other mutations. Optimization of the primers used in the
multiplex PCR resulted in a uniform coverage distribution over the amplicons that allows for efficient pooling of
samples in a sequencing run.
Conclusions: We show that a semi-conductor based sequencing approach to stratify colon and lung cancer patients is
feasible in a clinical setting.
Keywords: Next-generation sequencing, Semi-conductor sequencing, Colorectal cancer, Non-small cell lung cancer,
Multiplex PCR, Ion Torrent
Background
Although molecular mechanisms underlying carcinogen-
esis have been the subject of medical research for decades,
only in the last few years has this information translated
into the clinical setting through ‘smart’ drugs targeting
specific molecular aberrations of neoplastic cells [1]. Tar-
get based agents were initially explored in unselected
cohorts of cancer patients, and this approach led to failure
of the majority of clinical trials with these new agents.
More recently, the value of selecting patients to be treated
with targeted agents on the basis of specific molecular al-
terations of neoplastic cells has been acknowledged [2,3].
This new therapeutic approach has led to the approval of
novel drugs for molecularly selected patient populations.
These agents have revolutionized the treatment of cancer
patients, improving treatment outcome, while minimizing
side effects.
The number of predictive biomarkers that are assessed
in clinical practice is rapidly increasing with the availabil-
ity of drugs that target specific molecular alterations [4].
In some tumor types, such as non-small-cell lung carcin-
oma (NSCLC) and colorectal carcinoma (CRC), a new
classification based on the identification of specific
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predictive and/or prognostic molecular alterations has
emerged in the past decade [5,6]. However, molecular diag-
nostics is faced with its own specific challenges. Costs per
test, turn-around-time and the amount of material required
for testing increase with the number of tests performed on
a sample. In particular, the availability of tissue is limiting in
NSCLC, which is often diagnosed on small histological or
cytological samples yielding limited amounts of DNA [7].
Comprehensive molecular characterization of tumor
tissue in clinical practice will rely on the development of
high throughput technologies allowing this process to be
accomplished in a cost-effective and timely manner and
by using a limited amount of tissue. Two different ap-
proaches, genotyping assays and next generation sequen-
cing (NGS) have been proposed for molecular screening
[4,8]. NGS has the advantage to providing information
on known and novel molecular alterations. Indeed, by
using NGS-based techniques multiple genes can be se-
quenced simultaneously, and benchtop sequencers, like
the Ion PGM™ (Life Technologies), are fast and relatively
inexpensive. In this context, the ‘OncoNetwork consor-
tium’, a European collaborative effort developed and
tested the performance of a next-generation sequencing
approach in a clinical setting. The advantages of a multi-
lab collaboration are that methods can be quickly vali-
dated, facilitating availability, and that tests are evaluated
in different laboratory settings, assessing robustness. As
a proof-of-principle we chose to focus on CRC and
NSCLC, two frequent tumor types for which there are
known mutations associated with treatment decisions.
We decided to design an Ion AmpliSeq custom gene-
panel as a single multiplex PCR requiring only 10 ng of
input DNA for the detection of the most frequent hot
spot mutations in NSCLC and CRC. We opted for a
relatively small, focused gene-panel, instead of a broader
panel (like the AmpliSeq Cancer panel). Since a smaller
gene-panel requires less sequence capacity more samples
can be pooled in a single sequence run resulting in lower
costs per sample and an increased throughput compat-
ible with a diagnostic activity. Finally, we assessed the
performance of the panel by semiconductor sequencing of
155 CRC and NSCLC formalin-fixed, paraffin-embedded
(FFPE) cancer samples containing mutations previously
identified by alternative genotyping methods.
Methods
Tumor specimens and DNA isolation
FFPE tumor samples were retrieved from the archives of
the collaborating institutes and anonymised. Given the
study was interpreted by all institutions (Radboud univer-
sity medical centre, Istituto di ricovero e cura a carattere
scientifico (IRCCS), VIOLLIER, Applied Research On Can-
cer Centre (ARC-NET), Institut national de la santé et de la
recherche médicale (INSERM), Trinity College, Institut
Gustave-Roussy and University Hospitals Coventry and
Warwickshire) as a service improvement, it did not require
specific research ethics committee approval as stated in the
EU Clinical Trials Directive (2001/20/EC). Specific approval
was obtained from the SJH/AMNCH Joint Research Ethics
Committee of Trinity College, Dublin. Approval was pro-
cured for the current study as part of a wider study involv-
ing molecular analysis of a wider cohort and for research
purposes that does require approval from an ethics com-
mittee. A cover letter to this effect is available.
Tissue areas for DNA extraction were micro-dissected
and quantified for the percentage of neoplastic cells by a
pathologist. More details regarding sample characteristics
are depicted in Additional file 1: Figure S1. DNA extrac-
tion differed per institute. Most laboratories (6/7) isolated
DNA using the QIAamp DNA FFPE Tissue Kit, while one
lab purified DNA by overnight digestion in a proteinase
K/Chelex-100 solution.
Ion AmpliSeq™ primer design
Ion AmpliSeq™ primer pools were designed by Life Tech-
nologies (Additional file 2: Table S1 and Additional file 3:
Table S2). To minimize the risk of allelic drop-out during
the PCR due to primers that are not able to prime, no con-
firmed SNPs with a frequency >0.5% were allowed in the 5
most 3’ nucleotides. For the same reason low-frequency
SNPs at other positions were kept as low as possible, with a
maximum of four. Primer designs were confirmed by
SNPCheck v3 analysis (www.snpcheck.net/, April 2012).
The resulting oncopanel primer pool contained 87 primer
pairs with an average amplicon length of 203 bp (Additional
file 2: Table S1).
AmpliSeq enrichment and Ion Torrent sequencing
Library generation was performed according to the
manufacturer’s protocol. In short, 10 ng of DNA per
pool was amplified in 21 cycles by PCR using the Ion
AmpliSeq™ mastermix, followed by barcode and adapter
ligation. Amplified products were purified with Agen-
court AMPure XP beads (Beckman Coulter Genomics,
High Wycombe, UK). The library was diluted to 20 pM.
Emulsion PCR was performed using the Ion OneTouch™
200 Template kit following the protocol of the Ion One-
Touch™ System. Next, Ion Sphere Particles (ISPs) were
recovered and enriched for template positive ISPs using
Dynabeads MyOne Streptavidin C1 beads (Life Tech-
nologies) in the Ion OneTouch™ ES instrument (Life
Technologies). ISP enrichment was quantified using the
Qubit 2.0 fluorometer (Life Technologies). Sequencing
primer and polymerase were added to the final enriched
spheres before loading onto an Ion 316 chip according
to the Ion PGM™ 200 sequencing kit protocol.
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Data analysis
Sequence data were directly uploaded from the Ion
Torrent Suite Software to the IonReporter™ Software ver-
sion 1.2 and data were analyzed using a pre-configured
workflow specific for detecting low frequency somatic
variants. The allele frequency cut-off was set at 0.04. In
addition, the data were analyzed in parallel using a ‘hot-
spot bed file’ containing hotspot mutations in the regions
of our gene-panel derived from the COSMIC database.
The allele frequency cut-off for hotspot analysis was set at
0.02. These cutoffs were chosen following a preliminary
phase in which, starting from samples with known se-
quence, the best bioinformatic algorithm ensuring the
highest sensitivity and specificity was identified. The work-
flow includes mapping statistics, measurements of the
quality of all reads, on and off target statistics, SNP and
INDEL calling and comprehensive annotation using pub-
lic databases (dbSNP version 137, COSMIC version 60,
OMIM version 08012012, Gene Ontology version 1.218).
The variant caller algorithm was used and variants that
were identified for each sample per lab in each phase were
further filtered. We applied quality filtering by discarding
reads with a quality score <40 and checking against strand
bias. We filtered against variants with a variant allele
count less than 10, variants that showed up in every
sample of one lab with the same allele frequency, the syn-
onymous and non-coding variants and variants that were
known as polymorphisms or with a Minor Allele Fre-
quency (MAF) greater than 35%. As a result, a variant
knowledgebase was generated with the variants detected
in those samples. A specific workflow for this panel was
configured in the online Ion Reporter™ Software and was
used to perform analysis for data generated using the
Colon/Lung panel.
Results
Panel design and performance
The panel was designed in order to contain well-known
predictive markers in the receptor tyrosine kinase (RTK)
pathway, such as mutations of the EGFR (for NSCLC) and
KRAS (for NSCLC and CRC) genes, but also included
genes that might serve as targets in the near future or
have a prognostic relevance, like BRAF [9,10], AKT1 [11],
DDR2 [12,13] and ERBB2 [14-16] (Table 1). Selection of
the gene regions was based on their mutation frequencies,
based on the COSMIC database (Table 1). In particular,
the entire gene-panel targets 87 hotspot regions for the
following 22 genes: RTKs (ALK, EGFR, ERBB2, ERBB4,
Table 1 Mutation frequency of genes for which hotspot regions are present in the gene-panel
Gene Chr RefSeq Function % Mutated CRC# % Mutated lung cancer#
AKT1 14 NM_005163.2 Oncogene 0.64 0.42
ALK 2 NM_004304.3 Oncogene 2.74 5.25
BRAF 7 NM_004333.4 Oncogene 12.19 2.46
CTNNB1 3 NM_001904.3 Oncogene 4.61 3.13
DDR2 1 NM_006182.2 Oncogene 0 0.21
EGFR 7 NM_005228.3 Oncogene 2.75 26.71
ERBB2 17 NM_004448.2 Oncogene 1.48 1.80
ERBB4 2 NM_005235.2 Oncogene 3.84 8.35
FGFR1 8 NM_023110.2 Oncogene 0.55 1.62
FGFR2 10 NM_000141.4 Oncogene 0.42 1.68
FGFR3 4 NM_000142.4 Oncogene 0.53 0.92
KRAS 12 NM_004985.3 Oncogene 34.51 16.23
MAP2K1 15 NM_002755.3 Oncogene 0.15 1.14
MET 7 NM_001127500.1 Oncogene 0.73 3.03
NOTCH1 9 NM_017617.3 Oncogene 0.13 3.44
NRAS 1 NM_002524.3 Oncogene 3.37 0.88
PIK3CA 3 NM_006218.2 Oncogene 11.90 4.08
FBXW7 4 NM_0033632.2 Tumor suppressor 6.83 3.00
PTEN 10 NM_000314.4 Tumor suppressor 3.86 3.59
SMAD4 18 NM_005359.5 Tumor suppressor 7.89 2.68
STK11 19 NM_000455.4 Tumor suppressor 1.28 8.40
TP53 17 NM_000546.5 Tumor suppressor 41.75 37.64
#Data was extracted from the COSMIC database (http://cancer.sanger.ac.uk/cancergenome/projects/cosmic/) February 4th 2013.
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FGFR1, FGFR2, FGFR3, MET, DDR2); RTK signaling genes
(KRAS, PIK3CA, BRAF, AKT1, PTEN, NRAS, MAP2K1,
STK11); and other well known cancer-related genes
(NOTCH1, CTNNB1, SMAD4, FBXW7, TP53).
Dilution experiments with an artificial control sample
containing 10 hotspot mutations in the BRAF, EGFR,
KRAS, NRAS and PIK3CA genes (Horizon Diagnostics)
demonstrated that hotspot mutations could be confiden-
tially identified as low as 2% mutant alleles provided that
the coverage was >500× (results not shown). Preliminary
testing of the lung/colon cancer primer pool showed that
up to 5 samples could be pooled on a 316 chip (Ion
PGM™ Sequencer) with a minimal average read-depth of
500× (results not shown).
Experimental design
The above described panel, from now on called version 1
(v1), was used to test 155 FFPE tissue samples that con-
tained mutations previously identified by other methods.
In particular, the performance of the panel was assessed in
three phases (Figure 1). The first phase aimed at setting
up the AmpliSeq protocols, workflow and data analysis
and to define accuracy and precision of the panel. To this
end, 7 consortia labs tested 5 control samples in an inter-
laboratory ‘ring-trial’, i.e. 2 AcroMetrix® controls (FFPE
colon cancer cell lines, A12 and A13), 2 FFPE xenograft
colon tumours (X23 and X32) and one FFPE lung sample
(L1). All labs correctly identified in the control samples
the mutations previously detected by Sanger sequencing
(Table 2).
By using the panel, all 7 labs also identified 6 new vari-
ants in the two AcroMetrix® control samples (Table 2).
To confirm that these new variants are not sequencing
artifacts, we re-analyzed these positions by conventional
Sanger sequencing. All 6 new variants were confirmed
suggesting the specificity of our workflow (data not
shown). The two xenograft samples were not analyzed
for new variants since off-target amplification of mouse
DNA hampered data analysis.
In the second phase, we designed a ring-trial in which 6
labs selected 10 FFPE specimens (5 lung and 5 colon car-
cinoma FFPE samples) previously tested in a diagnostic
setting (for sample characteristics see Additional file 1:
Figure S1A). These samples were tested, in the blind, by a
second consortium lab. In total, the selected 60 samples
contained 47 previously identified mutations (42 missense
and 5 indels) in the KRAS, EGFR, BRAF and CTNNB1
genes (Table 3). All previously detected mutations were
detected using our oncopanel v1 and the IonReporter
variant caller.
In the third and final phase, each lab selected 15 in-
house samples representative of the type of samples
encountered in a diagnostic clinical setting and that are
problematic to analyze due to paucity of material, such as
small biopsies or cytological material, low percentage of
neoplastic cells and poor DNA quality (for sample charac-
teristics see Additional file 1: Figure S1B). In total 29 CRC
and 61 NSCLC samples were selected. In these samples,
56 mutations in the KRAS, EGFR and BRAF genes (46
missense and 10 indels) were previously identified in 54
unique samples using different methods (Additional file 4:
Table S3). DNA of 1 sample failed to amplify due to low
quality (technical failure 1.1%). All other samples could be
analyzed and all known variants were identified. Two add-
itional samples were excluded from further in-depth ana-
lyses (2.2%), since these samples contained a high number
of variants (>15) with an allele frequency of 4-7%, prob-
ably due to (over) fixation with formalin [17]. In the
remaining 87 assessable samples, we identified 92 new
variants in regions that were not analyzed with the
Figure 1 Schematic scheme of the 3 phases to assess the performance of the gene-panel.
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previously used alternative method (mutations and low
frequency SNPs with a MAF <0.04). Most of these new
variants were identified in the RTK-signaling genes BRAF,
EGFR, KRAS and PIK3CA (24 mutations) and in TP53 (30
mutations) (Figure 2 and Additional file 5: Table S4). Fur-
thermore, when taking the percentage of neoplastic cells
in individual samples and the allelic frequency of the vari-
ants into account, in contrast to most mutations in KRAS,
EGFR and BRAF, a large proportion of the newly identified
mutations appear to be present in only a subset of tumor
cells (Figure 2).
Thus, combining the data of all experiments, we ana-
lyzed 155 unique samples containing 112 previously iden-
tified mutations. All specimens were correctly genotyped,
except one that could not be analyzed due to poor quality
of the DNA, demonstrating excellent performance of the
gene panel.
Sequencing efficiency and panel re-design
While the level of concordance for mutational analysis
using this panel compared to classical Sanger sequencing
is excellent, we could ‘only’ multiplex 5 samples on a 316
chip to reach a minimal read depth of 500× per amplicon.
To determine if we could reduce the cost per sample by
multiplexing more samples per chip, we assessed the
sequencing efficiency by determining the read distribution
over the individual amplicons. While the average coverage
over the amplicons was reproducible among different labs
and runs (Figure 3A and not shown), the difference be-
tween the lowest and highest covered amplicons was sub-
stantial (average coverage of 3274 ± 2470 reads). While
this in itself is not a problem, the available sequencing
capacity of the chip is not efficiently used. Since an im-
proved primer design algorithm was introduced by Life
Technologies after the design of panel v1, the panel
primers were re-designed to attempt to optimize the
read distribution over the amplicons (Additional file 3:
Table S2). Moreover, the amplicons were designed to be
smaller to facilitate the amplification of DNA extracted
from FFPE specimens (91 amplicons, average size 158 bp).
As shown in figure 3B, the read distribution of v2 over the
Table 2 Variants identified in the 5 control samples
Sample Known mutations Mutations identified by NGS‡ Allele frequency#
L1 KRAS: p.Gly12Cys KRAS: p.Gly12Cys 0.44 - 0.54
A12 KRAS: p.Gly12Ala KRAS: p.Gly12Ala 0.66 - 0.67
FBXW7: p.His460Tyr 0.46 - 0.49
TP53: p.Ala159Asp 0.74 - 0.75
A13 KRAS: Gly13Asp KRAS: Gly13Asp 0.50 - 0.56
PIK3CA: p.Asp549Asn 0.43 - 0.46
DDR2: p.Thr98Ala 0.47 - 0.56
FGFR1: p.Ala268Ser 0.50 - 0.66
NOTCH1: p.Pro1581Leu 0.48 - 0.54
X23 KRAS: p.Gly12Asp KRAS: p.Gly12Asp 0.65 - 0.75
PIK3CA: p.Glu545Lys PIK3CA: p.Glu545Lys 0.40 - 0.51
X32 KRAS: p.Gly12Asp KRAS: p.Gly12Asp 0.54 - 0.69
PIK3CA: p.Glu542Lys PIK3CA: p.Glu542Lys 0.44 - 0.46
FBXW7: p.Arg465His FBXW7: p.Arg465His 0.46 - 0.55
TP53: p.Gly244Asp TP53: p.Gly244Asp 0.32 - 0.35
‡Newly identified variants were verified by conventional Sanger sequencing.
#Indicated is the range of the allele frequencies over the different laboratories.
Table 3 Known mutations present in the 60 samples that
were analyzed in the blind during phase 2 of the panel
validation
Mutation Unique samples Identified
BRAF: p.Val600Glu 3 Yes
CTNNB1: p.Thr41Ile 1 Yes
CTNNB1: p.Asp32Asn 1 Yes
EGFR: p.Glu746_Arg748del 1 Yes
EGFR: p.Glu746_Ala750del 4 Yes
EGFR: p.Glu746_Ser752del 1 Yes
EGFR: p.Leu858Arg 5 Yes
KRAS: p.Gln61Arg 1 Yes
KRAS: p.Gly12Arg 2 Yes
KRAS: p.Gly12Cys 5 Yes
KRAS: p.Gly12Asp 8 Yes
KRAS: p.Gly12Ala 2 Yes
KRAS: p.Gly12Val 7 Yes
KRAS: P.Gly13Cys 1 Yes
KRAS: p.Gly13Asp 5 Yes
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Figure 2 Schematic representation of the results of phase 3 of the panel validation. Indicated are the variants per sample identified in the
28 CRC (A) and 59 NSCLC (B) samples. Variant frequencies were extrapolated to 100% neoplastic cells and/or related to other variants present in
the sample (intra-sample comparison). Variants in black correspond to ‘driver’ mutations (present in >35% of neoplastic alleles), while variants in
grey are present in only a minority of the neoplastic cells (<35% of neoplastic alleles or an allele frequency 0.5x that of the driver mutation
present in the sample). Genes containing >1 variant in different frequencies are indicated in grey/black boxes.
Figure 3 Average coverage distribution over the individual amplicons. The coverage distribution plot over the individual amplicons in
gene-panel v1 (A) and v2 (B). For panel v1 5 samples are pooled per 316 chip; with panel v2 8 samples are pooled per 316 chip (B). Note the
logarithmic scale of the y-axis.
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individual amplicons was superior to v1 (lowest and high-
est covered amplicons within 10 fold range). Due to the
improved read distribution, up to 8 samples could be
pooled on a 316 chip with an average read depth of 2751 ±
1107 reads.
To check the performance of the panel, the 5 control
samples of phase 1 were-resequenced by all 7 laborator-
ies, and the expected variants as well as the new variants
identified in the two Accrometrix control samples were
detected using panel v2. In addition, the new panel was
used by 5 labs to re-sequence their 15 in-house samples
(75 samples in total) previously tested with panel v1, and
6 labs also tested 5 samples not previously analyzed (not
all labs were able to participate). All mutations previ-
ously detected with panel v1 were again identified using
panel v2 (data not shown), demonstrating that this panel
performs as well as v1 for these mutations. However,
since 8 samples can be multiplexed on a 316 chip with
panel v2, instead of 5 samples using v1, the sequencing
costs per sample are significantly reduced.
Discussion
Specification of the molecular class of NSCLC and CRC is
mandatory to optimize personalized medicine for these dis-
eases. However, a comprehensive molecular characterization
of the tumor is faced with a number of challenges, including
cost per test, turn-around-time and the limited amount of
material available for genotyping. NGS-based approaches
can overcome these challenges by providing in a single ana-
lysis information on tumor inter- and intra-heterogeneity
that can be relevant in a clinical setting. In this respect, a
number of NGS panels for tumor profiling have become
commercially available. However, these panels lack of valid-
ation in clinical samples and their inter-laboratory reprodu-
cibility has not been shown. In this study we propose a
novel model of collaboration between clinical research la-
boratories and NGS-companies that led to the development
of a tool that is ready for application in a clinical setting. In-
deed, the validation of panels through a consortium of aca-
demic institutions represents a novel approach to speed the
development of new diagnostic tools, being able to provide
information on a significant number of clinical specimens
and on inter-laboratory reproducibility.
We must acknowledge that there are still several issues
that need to be addressed to implement NGS panels in
the clinic. Our panel included 22 genes, although the ap-
proved predictive biomarkers in colon and lung cancer are
quite few (KRAS, NRAS, EGFR, ALK). Nevertheless, in
many cancer comprehensive centers clinical trials with
new drugs are open and molecular pathologists are re-
quested to screen for a number of biomarkers that are in-
cluded in the Colon and Lung cancer panel that we
developed. For example, among the 61 difficult NSCLC
samples analyzed in the third phase, we identified 18
EGFR, 7 PIK3CA and 3 BRAF mutants. Since drugs tar-
geting these latter molecular alterations are in clinical tri-
als, the availability of this information might significantly
improve the possibility of these patients to receive a per-
sonalized therapy [5]. It is possible that novel biomarkers
will be discovered in the future. In this respect, one advan-
tage of this panel is that it can be easily adapted by adding
new amplicons/genes of interest. Of course, a re-
validation on a minimum number of samples is recom-
mended for any modification of the panel.
The performance of a new test is a key element in
evaluating the possibility to introduce it in clinical diag-
nostics. In this regard, we chose to analyze our data with
an allele frequency cut-off of 4% for all variants and 2%
for known hotspot mutations corresponding to 5-10%
neoplastic cells carrying heterozygous mutations. This
estimate is in agreement with a previous study that
assessed somatic mutations in FFPE material by using
semiconductor-based massive parallel sequencing [18].
The allele frequency cut-off required for the detection of
somatic mutations is debatable, but samples with <10%
neoplastic cells are also difficult to diagnose by classical
histomorphological methods. Using this allele-frequency
cut-off we tested 155 clinical FFPE samples that were
previously analyzed by conventional methods. A sub-
stantial number of these specimens were specifically
selected based on the fact that they were difficult to
analyze with routine techniques. Even with this bias in
sample selection we were still able to correctly analyze
154 of the 155 samples. Although our sample set was
selected for certain mutations, our specimens contained
variants that represent the full spectrum of mutations
that are identified in NSCLC and CRC specimens. These
include a variety of indel and missense mutations of
which also hotspot mutations present in only 2% of the
alleles were readily detected. Other studies have previ-
ously suggested that semiconductor-based sequencing of
FFPE tissue is indeed feasible [18-20]. However, this is
the first study that evaluated a so large collection of
FFPE samples.
Other mutation-detection techniques, like quantitative
PCR (qPCR) or high resolution melting (HRM), can also
reach this level of sensitivity, but lack information regarding
the allele-frequency of the mutation. For example, EGFR
mutations showed allelic frequencies ranging between 20%
and 210% (amplification), after normalization for the per-
centage of neoplastic cells. This information could be clinic-
ally relevant in the near future as suggested by a report
showing that the duration of the response to target based
agents might be related to the relative content of mutant al-
leles in the tumor [21]. A quantitative assessment of the dif-
ferent mutant clones in polyclonal tumors will also be useful
for treatment decision, as recently shown for EGFR sensitiz-
ing and resistance mutations in NSCLC [22]. In addition,
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genotyping techniques can only provide information on
known mutations whereas sequencing-based methods can
also detect novel and rare mutations. Some of the new
variants we identified might not be true somatic mutations.
Variants with high allelic frequencies could also represent
infrequent SNPs, while especially non-hotspot variants with
low allelic frequencies could be false positive calls. These are
difficult to confirm however with standard methods like
Sanger sequencing. It must be emphasized that during this
project we used IonReporter Software version 1.2, while
currently version 1.6 is available with improved mutation
calling, especially in homopolymer regions.
Conventional methods, like Sanger sequencing or
qPCR, are singleplex tests and, as the number of targets
increases, the amount of DNA required for multiple
tests is a limiting factor. This can be problematic espe-
cially in lung cancer, since molecular analyses are often
performed on fine needle aspiration (FNA) biopsies or
cytology samples yielding limited amounts of DNA. Our
single multiplex PCR, consisting of 87 amplicons target-
ing 22 genes and requiring as little as 10 ng of input
DNA, overcomes this problem. Analyzing a similar
number of amplicons by conventional methods would
require 500–1000 ng of DNA, clearly demonstrating the
advantage of NGS.
Turn-around-time (TAT) is an important variable to
take into account in clinical diagnostics. We opted for
the IonPGM in our institutes since benchtop sequencers,
like the Ion PGM or the MiSeq only need hours to gen-
erate sequence data. In combination with a sample prep-
aration that is fast, like the Ion AmpliSeq™ gene-panel
presented here, the TAT from DNA isolation to results
is between 48 and 72 hours. While this may not be as
fast as some conventional methods, it is adequate for
most routine clinical applications.
An additional important consideration is cost. NGS in
general is cheap if costs are calculated per sequenced base.
However, clinical diagnostic laboratories do not need to
sequence hundreds of genes (yet), and neither can they af-
ford to batch numerous samples because of the short TAT
needed for clinical specimens. It is therefore important
that the sequencing capacity of the NGS platform is flex-
ible and can be adjusted based on the requirements per
experiment (e.g. the number of clinical specimens may
vary from day to day). A second consideration is that the
available sequence capacity on the chip is efficiently used.
Since our custom panel specifically investigates genetic
aberrations of interest for CRC and NSCLC, the required
sequencing capacity for our panel is smaller compared to
commercial panels that have been designed for a broad
spectrum of cancers. We estimate the bill of materials
costs between €130 and €175 per sample (excluding sales
tax, depreciation and overhead costs) using the re-
designed panel. While this may be higher compared to a
single conventional diagnostic test, it is actually a lot cheaper
considering that the NGS approach replaces multiple con-
ventional tests (Additional file 6: Table S5 and [18]).
Conclusion
The rapidly changing landscape in the field of tumor mo-
lecular characterization requires the analysis of an increas-
ing amount of targets. With the availability of fast bench
top sequencers such as the Ion Torrent PGM, massive
parallel sequencing becomes available for clinical labora-
tories. Here we showed that the development and valid-
ation of new tests is feasible with a multi-lab effort, and
believe it will facilitate the introduction of these tests into
clinical settings. We also demonstrated that implementa-
tion of massive parallel sequencing using dedicated gene-
panels can be fast, cost-effective and accurate. More
importantly, this novel approach might facilitate the
adoption of a molecular classification of lung and colon
carcinoma in clinical research, thus improving the possi-
bility to identify tumors carrying actionable molecular
alterations. Finally, we want to highlight that organization
of consortia similar to the one that we established in this
study might represent a novel approach to have a rapid,
un-biased validation among academic Institutions of new
testing methods in a clinical scenario.
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